Genmab A/S ADR (GMAB) News

Genmab A/S ADR (GMAB): $38.59

-0.34 (-0.87%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GMAB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter GMAB News Items

GMAB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GMAB News Highlights

  • GMAB's 30 day story count now stands at 6.
  • Over the past 13 days, the trend for GMAB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about GMAB are ACDC, CORR and EVBG.

Latest GMAB News From Around the Web

Below are the latest news stories about GENMAB A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 5,408 restricted stock units to employees of the Company as well as the Company’s subsidiaries and 5,138 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted sto

Yahoo | January 24, 2023

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022

Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 millio

Yahoo | January 24, 2023

GILD or GMAB: Which Is the Better Value Stock Right Now?

GILD vs. GMAB: Which Stock Is the Better Value Option?

Yahoo | January 23, 2023

Artisan Mid Cap Fund Exited Its Position in Genmab A/S (GMAB) For Better Opportunities

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, its Investor Class fund ARTMX returned -1.13%, Advisor Class fund APDMX posted a return of -1.12%, and Institutional Class fund APHMX returned -1.07%, compared to a […]

Yahoo | January 20, 2023

Correction to Company Announcement No. 1 of January 3, 2023

Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that member of the Board of Directors, Mijke Zachariasse, acquired a total of 175 shares in Genmab A/S due to vesting of restricted stock units (partly as employee of Genmab B.V., partly as board member). The corr

Yahoo | January 19, 2023

New Strong Buy Stocks for January 11th

GMAB, OSW, ACDC, EVBG and MTG have been added to the Zacks Rank #1 (Strong Buy) List on January 11 , 2023.

Yahoo | January 11, 2023

3 Biotech Companies to Watch in 2023

These biotech companies to watch are remarkably strong businesses that offer healthy upside potential as we head into a new year.

Muslim Farooque on InvestorPlace | January 6, 2023

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; January 3, 2023 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading

Yahoo | January 3, 2023

Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; January 2, 2023Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco at 9:00 AM PST / 12:00 PM EST / 6:00 PM CET on January 11, 2023. The live and archived webcast of the presentation will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is an international biotechnology com

Yahoo | January 2, 2023

Cashing out in biotech in 2022: On-target predictions for AbbVie, Vertex and Genmab

Seeking Alpha contributors accurately predicted the 2022 bull run of AbbVie (ABBV), Vertex Pharma (VRTX), and Genmab (GMAB), sometimes even against the consensus. Read the full story here.

Seeking Alpha | January 1, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5301 seconds.